1. Analyst View
2. Research Methodology
3. Market Drivers
3.1 Inclining Healthcare Expenditure
3.2 Rising Disposable Incomes
3.3 Increasing Ageing Population
3.4 Patent Expiry of Blockbuster Drugs
3.5 Mergers & Acquisitions
4. Market Challenges
4.1 Surging Generic Drug Prices
4.2 Long Product Approval Process
4.3 Legal Controversies
5. Overview of Generics Sector
5.1 US Pharmaceutical Market
5.2 Share of Branded vs. Generics
5.3 Generics Drugs Market
6. Market Potential for Generic Drugs in Key Therapies Segments
6.1 Oncology
6.2 Obesity & Cholesterol
6.3 Mental Health (Antipsychotics & Anti-Depressants)
6.4 Hypertension (Angiotensin II Receptor)
6.5 Diabetes
6.6 Anti-Ulcerants (Proton Pump Inhibitors)
6.7 Thyroid
6.8 Respiratory
7. Market Trends & Developments
7.1 New Product Launch
7.2 Launch of Biosimilars (BioGenerics)
7.3 Progress in User Fees for Generic Manufacturers (GDUFA)
7.4 Revision of Pay-for-delay Agreement Policies
8. Regulatory Environment
8.1 Drug Efficacy Study Implementation (DESI) Program
8.2 Hatch-Waxman Act
8.3 Patent Infringement Litigations
8.4 Para IV & the 180-day Marketing Exclusivity
8.5 FDA Requirements
8.6 Generic Initiative for Value & Efficiency (GIVE)
8.7 Healthcare Bill 2013
8.8 Ban on “Pay for delay” Settlements
8.9 Patient Protection and Affordable Care Act
9. Competitive Landscape
9.1 Market Share of Leading Players
9.2 Market Share of Leading Generic Drugs
9.3 Profiles
9.3.1 Teva Pharmaceuticals USA
9.3.2 Actavis Plc
9.3.3 Mylan Inc.
9.3.4 Pfizer Inc.
9.3.5 Sandoz Inc. (Novartis)
9.3.6 Endo International Plc.
9.3.7 Lupin Limited
9.3.8 Dr. Reddy’s Laboratories Ltd.
9.3.9 Zydus Pharmaceuticals Inc.
9.3.10 Amneal Pharmaceuticals

List of Figures:

Figure 3-1: Personal Disposable Income (Billion US$), 2008-2013
Figure 3-2: Total Health Expenditure (Billion US$), 2008-2013
Figure 3-3: Share of Public & Private Health Expenditure (2008-2013)
Figure 3-4: Population above 65 Years (Million), 2008-2013
Figure 5-1: US Pharmaceutical Market (Billion US$), 2013-2018
Figure 5-2: US Pharmaceutical Supply Chain
Figure 5-3: Share of Branded and Generics Drugs by Revenue (2013)
Figure 5-4: Market Share by Total Prescriptions (2011-2013)
Figure 5-5: Generic Drugs Market (Billion US$), 2013-2018
Figure 6-1: Estimated Cancer Deaths (2012 & 2013)
Figure 6-2: Adult Obesity Rate (%), 2013 & 2030
Figure 6-3: Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
Figure 8-1: Generic Drugs Approval Process
Figure 9-1: Share of Key Players in Generics Market (2013)
Figure 9-2: Teva Pharmaceuticals - Generics Revenue Share by Geographic Regions (2014)
Figure 9-3: Actavis Plc - Revenue Share by Geographic Regions (2013)
Figure 9-4: Mylan Inc - Revenue Share by Geographic Regions (2013)
Figure 9-5: Mylan Inc - Generics Revenue Share by Geographic Region (2014)
Figure 9-6: Pfizer - Revenue Share by Business Segments (2013)
Figure 9-7: Pfizer - Revenue Share by Geographical Regions (2013)
Figure 9-8: Sandoz - Revenue Share by Business Segments (2014)
Figure 9-9: Novartis - Revenue Share by Geographic Regions (2014)
Figure 9-10: Endo International Plc - Revenue Share by Business Segments (2013)
Figure 9-11: Lupin Ltd - Revenue Share by Business Segments (2013)
Figure 9-12: Lupin Ltd - Generics Share in the US by Value (2012 & 2013)
Figure 9-13: Lupin Ltd - Revenue Share by Geographic Regions (2013)
Figure 9-14: Dr. Reddy’s Laboratory - Revenue Share by Business Segments (2013)
Figure 9-15: Dr. Reddy’s Laboratory - Revenue Share by Geographical Regions (2013)
Figure 9-16: Amneal Pharmaceuticals - Revenue (Million US$), 2007 & 2014

List of Tables:

Table 3-1: Total Health Expenditure (% of GDP), 2008-2013
Table 3-2: Blockbuster Drugs Going Off Patent (2014-2016)
Table 3-3: Premium Deals in the US Generics Industry (2013- 2015)
Table 6-1: Patent Expiration of Key Oncology Drugs
Table 6-2: Patent Expiration of Key Antipsychotic Drugs
Table 6-3: Patent Expiration of Key Antidepressant Drugs
Table 6-4: Patent Expiration of Key Human Insulin Drugs
Table 6-5: Patent Expiry of Key Thyroid Drugs
Table 6-6: Patent Expiry of Key Respiratory Drugs
Table 7-1: Generic Drugs Launched in the US Market (2013 & 2014)
Table 7-2: List of Biosimilars under Development in the US
Table 9-1: Top Generic Drugs by Sales (Million US$), 2013
Table 9-2: Top Generic Drugs by Prescription (2013)
Table 9-3: Teva Pharmaceuticals - Revenue by Business Segments (Million US$), 2013 & 2014
Table 9-4: Teva Pharmaceuticals - Generics Revenue by Geographic Regions (Million US$), 2013 & 2014
Table 9-5: Actavis Plc - Revenue by Business Segments (Million US$), 2012 & 2013
Table 9-6: Mylan Inc - Revenue by Business Segments (Million US$), 2013 & 2014
Table 9-7: Pfizer - Revenue by Business Segments (Million US$), 2011-2013
Table 9-8: Endo International Inc - Revenue by Companies (Million US$), 2011-2013
Table 9-9: Lupin Ltd - Revenue by Business Segments (Million US$), 2011-2013
Table 9-10: Dr. Reddy’s Laboratory - Revenue by Business Segments (Million US$), 2011-2013